Drug ID: 1d00000148
Drug Name: Azilsartan medoxomil
Generic Names: Edarbi
Category: Anti- Hypertensives And ACE Inhibitors
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose in adults is 80 mg taken once daily.
Recommended In: This medication is an angiotensin II receptor antagonist, prescribed for hypertension. It improves blood flow by widening blood vessels.
Directions For Use: It comes as a tablet to take by mouth, with or without food.
Storage: Store it at room temperature (25°C), and in an airtight container. Protect from moisture and light.
Dosage Forms: Tablet
Side Effects: Most Common - Low blood pressure.
Gastrointestinal - Nausea.
General - Weakness and fatigue.
Musculoskeletal - Muscle spasm.
Central Nervous System - Dizziness.
Respiratory - Cough.
In Case of Overdose: In the event of an overdose, supportive therapy should be instituted as dictated by the patient's clinical status. Azilsartan is not dialyzable.
Avoid If: Contraindicated during second or third trimester of pregnancy, diabetes, and known hypersensitivity.
Caution should be exercised in patients with history of blood vessel problems, poor blood circulation, heart, liver, or kidney disease, sugar, stroke, heart attack, dehydration, angioedema, low blood volume, any allergy, who are taking other medications, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery and get up slowly from bed while taking this medication.
Monitor blood pressure, blood electrolyte levels, and heart or kidney function regularly while taking this medication.
Drug Interaction: Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving azilsartan and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Dual Blockade of the Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Edarbi and other agents that affect the RAS.
Do not coadminister aliskiren with Edarbi in patients with diabetes. Avoid use of aliskiren with Edarbi in patients with renal impairment (GFR < 60 mL/min).
Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use.